Public access to clinical trials: Lessons from an organizational implementation of policy

被引:6
|
作者
Huang, Grant D. [1 ]
Altemose, Jane K. [2 ]
Oleary, Timothy J. [3 ,4 ]
机构
[1] US Dept Vet Affairs, Off Res & Dev, Cooperat Studies Program, Washington, DC USA
[2] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA
[3] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA
[4] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
关键词
Clinical trials; Access; Policy; ClinicalTrials.gov; Veterans; CLINICALTRIALS.GOV;
D O I
10.1016/j.cct.2017.04.002
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Efforts to make clinical trials and their results more publicly available have been increasing in recent years. However, there is a need to better understand ways to achieve these goals aimed at benefiting a diverse set of stakeholders. Since 2005, the U.S. Department of Veterans Affairs Office of Research and Development (ORD), part of the nation's largest integrated health care system, has required the clinical trials its funds to be registered in ClinicalTrials.gov as a condition of the award. Furthermore, summary results of studies active since 2007 have been included in the registry. This paper highlights ORD activities, challenges and lessons at investigator, study, and organizational levels. Key factors in ORD's approach include: a mission-oriented approach; leadership support; a working group for organizational policies and practices; prioritizing communication; and recognizing the needs of investigators. Making clinical trials available to the public should represent a focal point for groups desiring to maximize the contributions from such research. The ability to do so must involve a commitment by sponsors and a critical evaluation of the reasons, requirements and resources at multiple levels.
引用
收藏
页码:87 / 89
页数:3
相关论文
共 50 条
  • [41] Perioperative morbidity: lessons from recent clinical trials
    Thiele, Robert H.
    Huffmyer, Julie L.
    Raphael, Jacob
    CURRENT OPINION IN CRITICAL CARE, 2012, 18 (04) : 358 - 365
  • [42] Lessons from clinical trials: LCAS and other studies
    Herd, JA
    MULTIPLE RISK FACTORS IN CARDIOVASCULAR DISEASE: STRATEGIES OF PREVENTION OF CORONARY HEART DISEASE, CARDIAC FAILURE, AND STROKE, 1998, 12 : 267 - 274
  • [43] Lessons from clinical trials in African Burkitt lymphoma
    Magrath, Ian
    CURRENT OPINION IN ONCOLOGY, 2009, 21 (05) : 462 - 468
  • [44] Cardiac cell therapy: Lessons from clinical trials
    Menasche, Philippe
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2011, 50 (02) : 258 - 265
  • [45] Quench the Thirst: Lessons From Clinical Thirst Trials
    Arai, Shoshana R.
    Butzlaff, Alice
    Stotts, Nancy A.
    Puntillo, Kathleen A.
    BIOLOGICAL RESEARCH FOR NURSING, 2014, 16 (04) : 456 - 466
  • [46] LESSONS LEARNED FROM CLINICAL-TRIALS OF SEPSIS
    OPAL, SM
    JOURNAL OF ENDOTOXIN RESEARCH, 1995, 2 (03): : 221 - 226
  • [47] The lessons learned from randomized clinical trials of GERD
    Pace, F.
    Sonnenberg, A.
    Porro, G. Bianchi
    DIGESTIVE AND LIVER DISEASE, 2007, 39 (11) : 993 - 1000
  • [48] Lessons Learned from Radiation Oncology Clinical Trials
    Liu, Fei-Fei
    Okunieff, Paul
    Bernhard, Eric J.
    Stone, Helen B.
    Yoo, Stephen
    Coleman, C. Norman
    Vikram, Bhadrasain
    Brown, Martin
    Buatti, John
    Guha, Chandan
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6089 - 6100
  • [49] Lessons from clinical trials of alemtuzumab in multiple sclerosis
    Chaudhuri, Abhijit
    Behan, Peter O.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2013, 2 (02) : 92 - 95
  • [50] Antisense therapeutics: lessons from early clinical trials
    Flaherty, KT
    Stevenson, JP
    O'Dwyer, PJ
    CURRENT OPINION IN ONCOLOGY, 2001, 13 (06) : 499 - 505